Research programme: enzyme inhibitors - Arresto Biosciences

Drug Profile

Research programme: enzyme inhibitors - Arresto Biosciences

Alternative Names: AB 0023

Latest Information Update: 28 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arresto Biosciences
  • Class Monoclonal antibodies
  • Mechanism of Action Growth factor receptor antagonists; LOXL2 protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Inflammation; Pulmonary fibrosis

Most Recent Events

  • 28 Aug 2012 No development reported - Preclinical for Cancer in USA (Parenteral)
  • 28 Aug 2012 No development reported - Preclinical for Inflammation in USA (Parenteral)
  • 28 Aug 2012 No development reported - Preclinical for Pulmonary fibrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top